Cancer Family
Glandular Cell Neoplasm
CI-CAN-00000188Explore in graph →
Non-malignant2,825 active trials43 approved drugs426 evidence items
- NCIt
- C7132
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000188Explore in graph →
Clinical trials
10,211 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05665023 | Bevacizumab Plus Modiifed FOLFIRINOX in Ovarian, Fallopian Tube, or Primary Peritoneal Mucinous Carcinoma | unknown | Phase 2 | 37 | Yonsei UniversityOTHER | 1 | Dec 29, 2022 | clinicaltrials |
| NCT05662488 | FAPI PET for Response Evaluation and Prognosis Prediction in Liver and Biliary Cancer Patients Treated With PD-1 Combination Therapy | unknown | — | 25 | Peking Union Medical College HospitalOTHER | 1 | Dec 22, 2022 |
| clinicaltrials |
| NCT05660889 | Adrenal Vein Sampling as a Tool to Identify Biomarkers That Aid the Diagnosis of Adrenocortical Carcinoma(AVS for ACC) | unknown | — | 25 | Erasmus Medical CenterOTHER | 1 | Dec 21, 2022 | clinicaltrials |
| NCT05649163 | Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard Therapy | unknown | — | 306 | Shen LinOTHER | 1 | Dec 16, 2022 | clinicaltrials |
| NCT05578430 | AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING) | unknown | Phase 2 | 54 | Sun Yat-sen UniversityOTHER | 0 | Dec 15, 2022 | clinicaltrials |
| NCT05361538 | Study of Microwave Spherical Ablation and Traditional Microwave Ablation in Single Hepatocellular Carcinoma ≤5cm | unknown | N/A | 60 | Tianjin Third Central HospitalOTHER | 1 | Dec 14, 2022 | clinicaltrials |
| NCT05650151 | Peri-operative Vitamin D Therapy for Hepatectomy | unknown | N/A | 200 | National Taiwan University HospitalOTHER | 0 | Dec 14, 2022 | clinicaltrials |
| NCT04212273 | Diagnostic Efficacies of Sonazoid-CEUS and EOB-MRI in Patients With High Risk of HCC | unknown | N/A | 200 | Tianjin Third Central HospitalOTHER | 1 | Dec 13, 2022 | clinicaltrials |
| NCT02446366 | Hypofractionated Stereotactic Body Radiation Therapy for Patients With Prostate Cancer That Was Removed by Surgery | unknown | N/A | 24 | University of Southern CaliforniaOTHER | 1 | Dec 12, 2022 | clinicaltrials |
| NCT05557851 | Minnelide Along With Abraxane Plus Gemcitabine in Patients With Metastatic Adenocarcinoma of the Pancreas | unknown | Phase 1 | 36 | Minneamrita Therapeutics LLCINDUSTRY | 1 | Dec 9, 2022 | clinicaltrials |
| NCT05638256 | 68Ga-labeled NY104 PET Imaging in Patients | unknown | Early Phase 1 | 10 | Affiliated Hospital of Jiangnan UniversityOTHER | 1 | Dec 6, 2022 | clinicaltrials |
| NCT04459078 | Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma | unknown | Phase 2 | 63 | Hunan Cancer HospitalOTHER | 1 | Dec 2, 2022 | clinicaltrials |
| NCT05635149 | Predictive Factors for Outcomes of Fruquintinib Plus Immunotherapy in Colorectal Cancer | unknown | — | 100 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Dec 2, 2022 | clinicaltrials |
| NCT04077255 | EGFR-targeted Therapy for Gastric Cancer | unknown | Phase 2 | 19 | National Cancer Center, KoreaOTHER_GOV | 1 | Nov 30, 2022 | clinicaltrials |
| NCT05619016 | [68Ga]Ga-ABY-025 PET for Quantification of HER2-status in Solid Tumors | unknown | Phase 2 | 72 | Karolinska University HospitalOTHER | 1 | Nov 30, 2022 | clinicaltrials |
| NCT05631015 | Artificial Intelligence for Determination of Gastroscopy Surveillance Intervals | unknown | — | 2,000 | Xiuli ZuoOTHER | 1 | Nov 30, 2022 | clinicaltrials |
| NCT04503902 | Toripalimab Combined With Donafenib in the Treatment of Advanced Hepatocellular Carcinoma(HCC) | unknown | Phase 1 / Phase 2 | 46 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Nov 29, 2022 | clinicaltrials |
| NCT05627297 | Applying Artificial Intelligence to Optimize Early-stage Hepatocellular Carcinoma Treatment Based on Multi-modal Image(AI-HCC) | unknown | — | 200 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Nov 25, 2022 | clinicaltrials |
| NCT05620004 | Safety and Efficacy of Bifidobacterium Therapy in Patients With Advanced Liver Cancer Receiving Immunotherapy | unknown | Phase 1 / Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Nov 17, 2022 | clinicaltrials |
| NCT05617430 | Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 43 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Nov 15, 2022 | clinicaltrials |
| NCT04288141 | A Study to Measure the Expression of the HER2-HER3 Dimer in Tumour and Blood (Exosomes) Samples From Patients With HER2 Positive Breast Cancer Receiving HER2 Targeted Therapies(HERdi PREDICT) | unknown | — | 40 | King's College LondonOTHER | 1 | Nov 14, 2022 | clinicaltrials |
| NCT05593393 | A Long-term Follow-up Cohort Study in Patients With Intraductal Papillary Mucinous Neoplasm | unknown | — | 1,500 | Peking Union Medical College HospitalOTHER | 0 | Nov 14, 2022 | clinicaltrials |
| NCT05614466 | The SIMPLY-B Study | unknown | N/A | 100 | Nadine BarnesOTHER | 0 | Nov 14, 2022 | clinicaltrials |
| NCT04718909 | Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCC(REGSIN) | unknown | Phase 2 | 166 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Nov 10, 2022 | clinicaltrials |
| NCT00986661 | A Study to Assess PV-10 Chemoablation of Cancer of the Liver | unknown | Phase 1 | 78 | Provectus Biopharmaceuticals, Inc.INDUSTRY | 1 | Nov 2, 2022 | clinicaltrials |
| NCT05005195 | Yorkshire Kidney Screening Trial(YKST) | unknown | N/A | 5,850 | University of LeedsOTHER | 1 | Nov 2, 2022 | clinicaltrials |
| NCT03907800 | Neoadjuvant Nab-paclitaxel in Triple-negative or HER2-positive Breast Cancer(NeoPATH) | unknown | Phase 2 | 100 | Ruijin HospitalOTHER | 1 | Oct 27, 2022 | clinicaltrials |
| NCT03432299 | Radiofrequency Ablation of Low Risk Papillary Thyroid Microcarcinoma(RFAforPTMC) | unknown | N/A | 100 | Seoul National University HospitalOTHER | 1 | Oct 26, 2022 | clinicaltrials |
| NCT05575622 | Clinical Study for Combined Analysis of CTC and Exosomes on Predicting the Efficacy of Immunotherapy in Patients With Hepatocellular Carcinoma | unknown | — | 200 | Zhongnan HospitalOTHER | 1 | Oct 24, 2022 | clinicaltrials |
| NCT05587452 | Early Screening of Colorectal Cancer Based on Plasma Multi-omics Combining With Artificial Intelligence(RECOMMEND) | unknown | — | 950 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Oct 24, 2022 | clinicaltrials |
| NCT05257694 | Clinical Decision Biological Biomarker and Prognosis Prediction of Hepatocellular Carcinoma by Deep Learning | unknown | — | 1 | Ping LiangOTHER | 1 | Oct 21, 2022 | clinicaltrials |
| NCT05350943 | HAIC Combined With Toripalimab and Donafenib for Advanced BTC | unknown | Phase 2 | 70 | Lu Wang, MD, PhDOTHER | 1 | Oct 18, 2022 | clinicaltrials |
| NCT05573282 | Observation Study of Sequential Regorafenib Plus ICIs After HAIC for Advanced Hepatocellular Carcinoma | unknown | — | 50 | Sun Yat-sen UniversityOTHER | 1 | Oct 18, 2022 | clinicaltrials |
| NCT05582278 | HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC | unknown | Phase 2 | 60 | Wen LiOTHER | 1 | Oct 17, 2022 | clinicaltrials |
| NCT05580224 | Anatomical Radiofrequency Ablation for Small Hepatocellular Carcinoma | unknown | N/A | 87 | Seoul National University HospitalOTHER | 1 | Oct 14, 2022 | clinicaltrials |
| NCT05580835 | PET / MR With PSMA for Diagnosis and Staging of Hepatocellular Carcinoma | unknown | N/A | 100 | University of Sao PauloOTHER | 1 | Oct 14, 2022 | clinicaltrials |
| NCT05449873 | No-touch Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma Using Triple Cooled-Wet Electrodes | unknown | N/A | 73 | Seoul National University HospitalOTHER | 1 | Oct 13, 2022 | clinicaltrials |
| NCT05571956 | Establishment of Pancreas Cancer and Cancer-associated Fibroblast Using EUS-guided Biopsy Samples | unknown | N/A | 50 | Ajou University School of MedicineOTHER | 1 | Oct 10, 2022 | clinicaltrials |
| NCT05572528 | Lenvatinib Therapy in HCC Patients After LDLT | unknown | — | 30 | Kaoshiung Chang Gung Memorial HospitalOTHER | 1 | Oct 7, 2022 | clinicaltrials |
| NCT05565677 | Prognostic Value of Lung Cancer MicroAnatomy in 3D(LungCaMa3D) | unknown | — | 50 | Aristotle University Of ThessalonikiOTHER | 0 | Oct 4, 2022 | clinicaltrials |
| NCT05561686 | Real-world Study of Pyrotinib in Neoadjuvant Therapy for HER2-positive Breast Cancer | unknown | — | 100 | Hunan Cancer HospitalOTHER | 1 | Sep 30, 2022 | clinicaltrials |
| NCT03864211 | Thermal Ablation Followed by Immunotherapy for HCC | unknown | Phase 1 / Phase 2 | 145 | Xiangya Hospital of Central South UniversityOTHER | 1 | Sep 29, 2022 | clinicaltrials |
| NCT05085626 | Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive HER2 Negative Advanced Breast Cancer | unknown | Phase 2 | 40 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 29, 2022 | clinicaltrials |
| NCT05550025 | TACE Combined With Camrelizumab and Apatinib in the Treatment of Advanced Liver Cancer | unknown | Phase 2 | 26 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 22, 2022 | clinicaltrials |
| NCT04913025 | REduced Frequency ImmuNE Checkpoint Inhibition in Cancers(REFINE) | unknown | Phase 2 | 160 | University College, LondonOTHER | 1 | Sep 21, 2022 | clinicaltrials |
| NCT05545124 | Study of Donafenib Combined With Tislelizumab in the Adjuvant Treatment of Primary HCC With High Risk of Recurrence | unknown | Phase 2 | 32 | Henan Cancer HospitalOTHER_GOV | 0 | Sep 19, 2022 | clinicaltrials |
| NCT05546255 | Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer | unknown | Phase 2 | 40 | Chinese Academy of Medical SciencesOTHER | 1 | Sep 19, 2022 | clinicaltrials |
| NCT05544253 | Safety and Efficacy of Mitomycin C-based HIPEC After srHCC and PM of HCC | unknown | Phase 2 / Phase 3 | 68 | West China HospitalOTHER | 1 | Sep 16, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Dec 29, 2022source: clinicaltrials